Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Pierobon

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Iscience|November 8, 2019
Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast CancersSuriyan Ponnusamy, Sarah Asemota, Lee S Schwartzberg, et al.
NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.
Journal for Immunotherapy of Cancer|October 8, 2021
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicineElisa Baldelli, K Alex Hodge, Guido Bellezza, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Molecular Oncology|August 26, 2021
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trialMariaelena Pierobon, Nicholas J Robert, Donald W Northfelt, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Iscience|July 19, 2021
Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimensAllison L Hunt, Nicholas W Bateman, Waleed Barakat, et al.
Cancer Discovery|November 28, 2019
Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric CancerHaisheng Zhang, Antje Schaefer, Yichen Wang, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Iscience|November 8, 2019
Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast CancersSuriyan Ponnusamy, Sarah Asemota, Lee S Schwartzberg, et al.
NPJ Precision Oncology|May 31, 2024
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancersDaniel P Nussbaum, Colin A Martz, Andrew M Waters, et al.
Journal for Immunotherapy of Cancer|October 8, 2021
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicineElisa Baldelli, K Alex Hodge, Guido Bellezza, et al.
Cancer Research|November 8, 2022
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic CancerCraig M Goodwin, Andrew M Waters, Jennifer E Klomp, et al.
Molecular Oncology|August 26, 2021
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trialMariaelena Pierobon, Nicholas J Robert, Donald W Northfelt, et al.
Science Signaling|August 9, 2022
Functional and biological heterogeneity of KRAS<sup>Q61</sup> mutationsMinh V Huynh, G Aaron Hobbs, Antje Schaefer, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Iscience|July 19, 2021
Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimensAllison L Hunt, Nicholas W Bateman, Waleed Barakat, et al.
Cancer Discovery|November 28, 2019
Gain-of-Function <i>RHOA</i> Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric CancerHaisheng Zhang, Antje Schaefer, Yichen Wang, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Pageof 10